Related Experiment Videos
Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin
1Max-Planck-Gesellschaft e. V., Research Unit, Pharmacological Haemostaseology, Friedrich Schiller University, Jena, Germany.
Thrombosis Research
|November 15, 1995
Summary
Meizothrombin effectively neutralizes hirudin, a direct thrombin inhibitor, in blood. This prothrombin intermediate reduces hirudin
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Background:
- Hirudin is a direct thrombin inhibitor with anticoagulant properties.
- Ecarin converts prothrombin to meizothrombin, a stable intermediate.
- Understanding hirudin neutralization is crucial for managing anticoagulant therapies.
Purpose of the Study:
- To investigate the ability of meizothrombin to bind and neutralize hirudin in blood.
- To assess the efficacy of meizothrombin as an antidote for hirudin toxicity.
Main Methods:
- In vitro studies using rat plasma pre-incubated with ecarin.
- In vivo experiments in Wistar rats involving hirudin administration followed by ecarin infusion.
- Measurement of thrombin time, hirudin blood levels, platelet count, and fibrinogen levels.
Main Results:
- In vitro incubation with ecarin reduced hirudin's anticoagulant effect, dependent on incubation time.
- In vivo, ecarin administration after hirudin led to a sharp drop in hirudin blood levels.
- Bleeding was effectively stopped following ecarin infusion, with no significant changes in platelet count or fibrinogen.
Conclusions:
- Meizothrombin, generated by ecarin, effectively neutralizes hirudin in a biological context.
- Meizothrombin represents a potential therapeutic agent for neutralizing excessive hirudin levels.
- This study highlights the role of prothrombin intermediates in modulating anticoagulant activity.